دورية أكاديمية
أعرض في EDS

Long-Term Risk of Hospitalization Among Five-Year Survivors of Childhood Leukemia in the Nordic Countries.

التفاصيل البيبلوغرافية
العنوان: Long-Term Risk of Hospitalization Among Five-Year Survivors of Childhood Leukemia in the Nordic Countries.
المؤلفون: Sørensen GV, Winther JF, de Fine Licht S, Andersen KK, Holmqvist AS, Madanat-Harjuoja L, Tryggvadottir L, Bautz A, Lash TL, Hasle H
المصدر: Journal of the National Cancer Institute [J Natl Cancer Inst] 2019 Sep 01; Vol. 111 (9), pp. 943-951.
نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't
اللغة: English
بيانات الدورية: Publisher: Oxford University Press Country of Publication: United States NLM ID: 7503089 Publication Model: Print Cited Medium: Internet ISSN: 1460-2105 (Electronic) Linking ISSN: 00278874 NLM ISO Abbreviation: J Natl Cancer Inst Subsets: MEDLINE
أسماء مطبوعة: Publication: <2003-> : Cary, NC : Oxford University Press
Original Publication: Bethesda, Md., U. S. Dept. of Health, Education, and Welfare, Public Health Service, National Institutes of Health; Washington, for sale by the Supt. of Docs., U. S. Govt. Print. Off.
مواضيع طبية MeSH: Cancer Survivors* , Hospitalization*, Leukemia/*epidemiology, Adolescent ; Age Factors ; Age of Onset ; Child ; Child, Preschool ; Female ; Humans ; Incidence ; Infant ; Infant, Newborn ; Leukemia/diagnosis ; Leukemia/mortality ; Male ; Odds Ratio ; Patient Admission ; Prognosis ; Public Health Surveillance ; Scandinavian and Nordic Countries/epidemiology
مستخلص: Background: Adverse effects from childhood leukemia treatment may persist or present years after cure from cancer. We provide a comprehensive evaluation of subsequent hospitalization in five-year survivors of childhood acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), and chronic myeloid leukemia (CML).
Methods: In the Adult Life after Childhood Cancer in Scandinavia Study, we identified 4003 five-year survivors diagnosed with childhood leukemia 1970-2008 in Denmark, Sweden, Iceland, and Finland. Survivors and 129 828 population comparisons were followed for first-time nonpsychiatric hospitalizations for 120 disease categories in the hospital registries. Standardized hospitalization rate ratios and absolute excess rates were calculated. All statistical tests were two-sided.
Results: Survivors of ALL (n = 3391), AML (n = 389), and CML (n = 92) had an increased overall hospitalization rate compared with population comparisons. The rate ratio for any hospitalization was 1.95 (95% confidence interval [CI] = 1.83 to 2.07) in ALL, 3.09 (95% CI = 2.53 to 3.65) in AML, and 4.51 (95% CI = 3.03 to 6.00) in CML survivors and remained increased even 20 years from leukemia diagnosis. Corresponding absolute excess rates per 1000 person-years were 28.48 (95% CI = 24.96 to 32.00), 62.75 (95% CI = 46.00 to 79.50), and 105.31 (95% CI = 60.90 to 149.72).
Conclusion: Leukemia survivors have an increased rate of hospitalization for medical conditions. We provide novel insight into the relative and absolute rate of hospitalization for 120 disease categories in survivors of ALL, AML, and CML, which are likely to be informative for both survivors and healthcare providers.
(© The Author(s) 2019. Published by Oxford University Press. All rights reserved. For permissions, please email: journals.permissions@oup.com.)
التعليقات: Comment in: J Natl Cancer Inst. 2019 Sep 1;111(9):880-881. (PMID: 30753660)
References: Blood. 2001 Dec 15;98(13):3569-74. (PMID: 11739158)
APMIS Suppl. 1992;31:1-194. (PMID: 1301768)
Comput Methods Programs Biomed. 2004 Apr;74(1):69-75. (PMID: 14992828)
Blood. 2004 Sep 15;104(6):1898-906. (PMID: 15172972)
Cancer. 2005 Apr 1;103(7):1457-67. (PMID: 15712273)
N Engl J Med. 2006 Oct 12;355(15):1572-82. (PMID: 17035650)
J Clin Oncol. 2006 Dec 20;24(36):5750-62. (PMID: 17179109)
Cancer. 2008 May 1;112(9):2071-9. (PMID: 18327823)
Blood. 2008 Jun 15;111(12):5515-23. (PMID: 18334672)
J Clin Oncol. 2009 May 10;27(14):2339-55. (PMID: 19364955)
J Clin Oncol. 2009 Jun 1;27(16):2677-85. (PMID: 19364965)
N Engl J Med. 2009 Jun 25;360(26):2730-41. (PMID: 19553647)
Hematol Oncol Clin North Am. 2009 Oct;23(5):1065-82, vi-vii. (PMID: 19825453)
J Clin Oncol. 2010 Jan 10;28(2):324-31. (PMID: 19917844)
Leukemia. 2010 Feb;24(2):345-54. (PMID: 20010622)
J Natl Cancer Inst. 2010 Jul 21;102(14):1083-95. (PMID: 20634481)
Int J Cancer. 2011 Apr 1;128(7):1624-31. (PMID: 21280033)
Blood. 2011 Aug 4;118(5):1413-20. (PMID: 21652685)
BMC Public Health. 2011 Jun 09;11:450. (PMID: 21658213)
Curr Hematol Malig Rep. 2011 Sep;6(3):195-205. (PMID: 21695425)
Scand J Public Health. 2011 Jul;39(7 Suppl):22-5. (PMID: 21775345)
Scand J Public Health. 2011 Jul;39(7 Suppl):30-3. (PMID: 21775347)
Pediatr Blood Cancer. 2012 Mar;58(3):334-43. (PMID: 22038641)
Hematology Am Soc Hematol Educ Program. 2011;2011:238-42. (PMID: 22160040)
Pediatr Blood Cancer. 2012 Jul 15;59(1):126-32. (PMID: 22180128)
Blood. 2012 Oct 18;120(16):3187-205. (PMID: 22879540)
Scand J Public Health. 2012 Aug;40(6):505-15. (PMID: 22899561)
J Clin Oncol. 2013 Jul 1;31(19):2469-76. (PMID: 23690411)
JAMA. 2013 Jun 12;309(22):2371-2381. (PMID: 23757085)
Int J Cancer. 2014 Mar 1;134(5):1174-82. (PMID: 24037993)
Pediatr Blood Cancer. 2014 Apr;61(4):729-36. (PMID: 24285698)
Br J Cancer. 2014 Mar 4;110(5):1342-50. (PMID: 24366296)
Lancet. 2014 Jun 7;383(9933):1981-9. (PMID: 24556022)
Cancer. 2014 Aug 15;120(16):2514-21. (PMID: 24824782)
BMC Cancer. 2014 Jun 10;14:419. (PMID: 24917272)
Lancet Oncol. 2014 Jul;15(8):841-51. (PMID: 24954778)
Lancet Oncol. 2014 Jul;15(8):782-3. (PMID: 24954780)
Br J Haematol. 2015 Feb;168(4):518-25. (PMID: 25284463)
Int J Cancer. 2015 Sep 1;137(5):1176-86. (PMID: 25648592)
Pediatr Blood Cancer. 2015 Dec;62(12):2204-10. (PMID: 26193842)
J Clin Oncol. 2015 Sep 20;33(27):2938-48. (PMID: 26304874)
Clin Epidemiol. 2015 Nov 17;7:449-90. (PMID: 26604824)
Biol Blood Marrow Transplant. 2016 May;22(5):782-95. (PMID: 26802323)
PLoS One. 2016 Jul 19;11(7):e0159518. (PMID: 27433937)
Eur J Cancer. 2016 Nov;67:183-190. (PMID: 27677054)
Br J Haematol. 2017 Jan;176(2):168-178. (PMID: 27766626)
Cancer Med. 2017 May;6(5):1123-1134. (PMID: 28378525)
Lancet Oncol. 2017 Jun;18(6):719-731. (PMID: 28410997)
Lancet Haematol. 2017 May;4(5):e202-e217. (PMID: 28411119)
PLoS Med. 2017 May 9;14(5):e1002296. (PMID: 28486495)
Cancer Epidemiol. 2017 Aug;49:216-224. (PMID: 28734233)
Lancet. 2017 Dec 9;390(10112):2569-2582. (PMID: 28890157)
Hum Reprod. 2018 Jul 1;33(7):1281-1290. (PMID: 29912328)
Int J Cancer. 1987 Nov 15;40(5):620-4. (PMID: 3679589)
Acta Paediatr. 1998 Nov;87(11):1151-61. (PMID: 9846917)
تواريخ الأحداث: Date Created: 20190213 Date Completed: 20200615 Latest Revision: 20200615
رمز التحديث: 20240829
مُعرف محوري في PubMed: PMC6748786
DOI: 10.1093/jnci/djz016
PMID: 30753563
قاعدة البيانات: MEDLINE
الوصف
تدمد:1460-2105
DOI:10.1093/jnci/djz016